Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers.

Nakamura Y, Oshima K, Naoi Y, Nakayama T, Kim SJ, Shimazu K, Shimomura A, Maruyama N, Tamaki Y, Noguchi S.

Breast Cancer Res Treat. 2012 Jul;134(1):229-36. doi: 10.1007/s10549-012-1976-x.

PMID:
22315133
2.

Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.

Yasojima H, Shimomura A, Naoi Y, Kishi K, Baba Y, Shimazu K, Nakayama T, Kim SJ, Tamaki Y, Noguchi S.

Eur J Cancer. 2011 Aug;47(12):1779-88. doi: 10.1016/j.ejca.2011.06.017.

PMID:
21741827
3.

TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.

Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlböck M, Gnant M, Steger G, Jakesz R.

Clin Cancer Res. 2000 Jan;6(1):50-6.

4.

GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer.

Miyake T, Nakayama T, Naoi Y, Yamamoto N, Otani Y, Kim SJ, Shimazu K, Shimomura A, Maruyama N, Tamaki Y, Noguchi S.

Cancer Sci. 2012 May;103(5):913-20. doi: 10.1111/j.1349-7006.2012.02231.x.

5.

Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.

Naoi Y, Kishi K, Tanei T, Tsunashima R, Tominaga N, Baba Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S.

Cancer. 2011 Aug 15;117(16):3682-90. doi: 10.1002/cncr.25953.

6.

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.

Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de Thé H.

PLoS Med. 2007 Mar;4(3):e90.

7.

14-3-3σ regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF-7 breast cancer cells via Akt inactivation.

Zheng G, Xiong Y, Yi S, Zhang W, Peng B, Zhang Q, He Z.

FEBS Lett. 2012 Jan 20;586(2):163-8. doi: 10.1016/j.febslet.2011.11.034.

8.

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.

Knappskog S, Chrisanthar R, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, Lønning PE.

Breast Cancer Res. 2012 Mar 15;14(2):R47.

9.

Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.

Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG.

Cancer Res. 2000 Apr 15;60(8):2155-62.

10.

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators..

J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. doi: 10.1093/jnci/djn151.

PMID:
18505968
11.

p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.

Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L.

Clin Cancer Res. 2000 Jul;6(7):2751-8.

12.

Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer.

Oshima K, Naoi Y, Kishi K, Nakamura Y, Iwamoto T, Shimazu K, Nakayama T, Kim SJ, Baba Y, Tamaki Y, Noguchi S.

Cancer Lett. 2011 Aug 28;307(2):149-57. doi: 10.1016/j.canlet.2011.03.027.

PMID:
21514041
13.
14.

CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.

Esteva FJ, Wang J, Lin F, Mejia JA, Yan K, Altundag K, Valero V, Buzdar AU, Hortobagyi GN, Symmans WF, Pusztai L.

Breast Cancer Res. 2007;9(6):R87.

15.
16.

TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.

Wang J, Xu B, Yuan P, Zhang P, Li Q, Ma F, Fan Y.

Breast Cancer Res Treat. 2012 Sep;135(2):531-7. doi: 10.1007/s10549-012-2167-5.

PMID:
22864769
17.

Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.

Petit T, Wilt M, Velten M, Rodier JF, Fricker JP, Dufour P, Ghnassia JP.

Breast Cancer Res Treat. 2010 Nov;124(2):387-91. doi: 10.1007/s10549-010-1142-2.

PMID:
20824324
18.

TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.

Perrone F, Bossi P, Cortelazzi B, Locati L, Quattrone P, Pierotti MA, Pilotti S, Licitra L.

J Clin Oncol. 2010 Feb 10;28(5):761-6. doi: 10.1200/JCO.2009.22.4170.

PMID:
20048189
19.

[Neoadjuvant chemotherapy for primary breast cancer].

Li JF, Ouyang T, Wang TF, Lin BY.

Zhonghua Zhong Liu Za Zhi. 2004 Aug;26(8):493-5. Chinese.

PMID:
15555342
20.

Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.

Nishimura R, Osako T, Okumura Y, Hayashi M, Arima N.

Breast Cancer. 2010 Oct;17(4):269-75. doi: 10.1007/s12282-009-0161-5.

PMID:
19730975
Items per page

Supplemental Content

Support Center